Clinical Benefit With PARP Inhibitor for Pathogenic Germline FANCA-Mutated Relapsed Epithelial Ovarian Cancer: A Case Report

BACKGROUND: PARP inhibitors have been approved as targeted therapy for BRCA-deficient metastatic ovarian cancer (OC). Fanconi anemia complementation group A (FANCA), one of the homologous recombination repair pathway genes, is a susceptibility gene to breast cancer and OC. Therefore, it is interesti...

Descripción completa

Detalles Bibliográficos
Autores principales: Qian, Bing, Leng, Wenshu, Yan, Zhengqing, Lu, Jin, Chen, Shiqing, Yi, Huan, Jiang, Zhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913585/
https://www.ncbi.nlm.nih.gov/pubmed/35280757
http://dx.doi.org/10.3389/fonc.2022.778545

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913585/
https://www.ncbi.nlm.nih.gov/pubmed/35280757
http://dx.doi.org/10.3389/fonc.2022.778545

Ejemplares similares